ArticleNeurology(R) neuroimmunology & neuroinflammation2018
GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Autoimmune glial fibrillary acidic protein astrocytopathy with full-length spinal cord lesions: a case report and literature review.BMC neurology · 2026Review
- Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature.Antibodies (Basel, Switzerland) · 2024Review
- Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy.Brain sciences · 2022Article
- A New Perspective on the Pathophysiology of Idiopathic Intracranial Hypertension: Role of the Glia-Neuro-Vascular Interface.Frontiers in molecular neuroscience · 2022Article
- Case Report: Need for Caution in the Diagnosis of GFAP Astrocytopathy-A Case of GFAP Astrocytopathy Coexistent With Primary Central Nervous System Lymphoma.Frontiers in neurology · 2022Article
- Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.International journal of molecular sciences · 2021Review
- Monoclonal Antibodies as Neurological Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.BMJ neurology open · 2021Article
- Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management.Frontiers in neurology · 2021Review
- Ocrelizumab initiation in patients with MS: A multicenter observational study.Neurology(R) neuroimmunology & neuroinflammation · 2020Observational
- Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.Therapeutic advances in neurological disorders · 2020Article
- Management of MS Patients Treated With Daclizumab - a Case Series of 267 Patients.Frontiers in neurology · 2020Article
- Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.Drug safety · 2019Review
- Autoimmune glial fibrillary acidic protein astrocytopathy.Current opinion in neurology · 2019Review
- Review
- A fatal case of daclizumab-induced liver failure in a patient with MS.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.Therapeutic advances in neurological disorders · 2019Review
- Navigating choice in multiple sclerosis management.Neurological research and practice · 2019Review
- N2 year in review and message from the editor to our reviewers.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.Frontiers in neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe a case of glial fibrillary acidic protein (GFAP)α immunoglobulin G (IgG)-associated encephalitis in a patient referred to us with MS on daclizumab treatment and to summarize characteristics of 5 additional recent German MS cases of serious encephalitis along with a previously published American case of CNS vasculitis associated with daclizumab.
methodsEvaluation of cause, clinical symptoms, and treatment response.
resultsThe 6 patients included 4 women and 2 men. The median age at onset was 38 years (range 32-51 years). Clinical presentation was marked by progressing neuropsychologic and/or neurologic deficits. Additional drug rash with eosinophilia was seen in 3 patients, whereas 2 patients showed a highly active demyelinating process. Examination of CSF samples detected pleocytosis, elevated total protein levels, and GFAPα IgG antibodies, which were not found in serum. In our case, we discovered autoimmune GFAP astrocytopathy associated with encephalitis as secondary autoimmunity, which was steroid responsive. Clinical outcome of other cases was marked by partial recovery in 4 patients and persistent foster care in 1 patient.
conclusionsOur case of GFAPα IgG-associated encephalitis along with 12 other cases of serious inflammatory brain disorders following daclizumab treatment so far indicates that interfering with NK cells and Tregs by anti-CD25 antibody therapy can result in severe secondary CNS autoimmunity in man.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.